Updates are available Correction dated 2025-02-12
Click to view Correction: https://doi.org/10.1038/s41467-025-56808-8
-
Authors
Papes, Fabio
Camargo, Antonio P. https://orcid.org/0000-0003-3913-2484
de Souza, Janaina S. https://orcid.org/0000-0003-3904-7458
Carvalho, Vinicius M. A.
Szeto, Ryan A. https://orcid.org/0000-0003-0213-4443
LaMontagne, Erin https://orcid.org/0000-0003-0017-8223
Teixeira, José R. https://orcid.org/0000-0003-3704-7649
Avansini, Simoni H. https://orcid.org/0000-0002-2490-7438
Sánchez-Sánchez, Sandra M.
Nakahara, Thiago S. https://orcid.org/0000-0001-7442-3338
Santo, Carolina N. https://orcid.org/0000-0001-6565-3975
Wu, Wei https://orcid.org/0000-0002-1541-333X
Yao, Hang
Araújo, Barbara M. P.
Velho, Paulo E. N. F. https://orcid.org/0000-0001-7901-2351
Haddad, Gabriel G.
Muotri, Alysson R. https://orcid.org/0000-0003-0867-2875
- License Information
-
More Information
Article History
Received: 6 July 2021
Accepted: 31 March 2022
First Online: 2 May 2022
Change Date: 12 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-56808-8
Competing interests
: Dr. Muotri is the co-founder of and has an equity interest in TISMOO, a company dedicated to genetic analysis and human brain organogenesis, focusing on therapeutic applications customized to autism spectrum disorders and other neurological diseases. The terms of this arrangement have been reviewed and approved by the University of California San Diego, in accordance with its conflict-of-interest policies. UCSD has filed a patent application (WO2022072709A1), in which F.P. and A.R.M. are inventors, containing some results regarding the TCF4 correction overexpression strategy described in this paper. The patent was published on 04-07-2022. Other authors declare no competing interests.
